Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete | ||
Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
Samsca | Tolvaptan | Hyponatremia, non-hypovolemic | Do not list | Complete | ||
Xeljanz | tofacitinib | Cancelled | ||||
Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Xeljanz | Tofacitinib | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
Actemra | tocilizumab | Giant cell arteritis (GCA) | Reimburse with clinical criteria and/or conditions | Complete | ||
Actemra | Tocilizumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | ||
Actemra | Tocilizumab | Arthritis, polyarticular juvenile idiopathic | List with criteria/condition | Complete | ||
Actemra | Tocilizumab | Arthritis, rheumatoid | List with criteria/condition | Complete |